Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) FCF Margin (2020 - 2025)

Historic FCF Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 12.46%.

  • Burning Rock Biotech's FCF Margin rose 989900.0% to 12.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.43%, marking a year-over-year increase of 306000.0%. This contributed to the annual value of 18.94% for FY2024, which is 301600.0% up from last year.
  • Per Burning Rock Biotech's latest filing, its FCF Margin stood at 12.46% for Q3 2025, which was up 989900.0% from 45.69% recorded in Q2 2025.
  • Over the past 5 years, Burning Rock Biotech's FCF Margin peaked at 15.12% during Q4 2024, and registered a low of 321.17% during Q4 2022.
  • Its 5-year average for FCF Margin is 70.97%, with a median of 76.24% in 2021.
  • As far as peak fluctuations go, Burning Rock Biotech's FCF Margin tumbled by -2449300bps in 2022, and later soared by 3079400bps in 2023.
  • Over the past 5 years, Burning Rock Biotech's FCF Margin (Quarter) stood at 76.24% in 2021, then crashed by -321bps to 321.17% in 2022, then soared by 96bps to 13.23% in 2023, then soared by 214bps to 15.12% in 2024, then dropped by -18bps to 12.46% in 2025.
  • Its FCF Margin was 12.46% in Q3 2025, compared to 45.69% in Q2 2025 and 17.68% in Q1 2025.